Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumors.
Occludin is a key component of tight junctions. Reduced occludin expression has been linked to cancer progression in individual tumor types, but a comprehensive and standardized analysis across human tumor types is lacking. To study the prevalence and clinical relevance of occludin expression in can...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0321105 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850216171842830336 |
|---|---|
| author | Seyma Büyücek Florian Viehweger Viktor Reiswich Natalia Gorbokon Viktoria Chirico Christian Bernreuther Florian Lutz Simon Kind Ria Schlichter Sören Weidemann Till S Clauditz Andrea Hinsch Ahmed Abdulwahab Bawahab Frank Jacobsen Andreas M Luebke David Dum Claudia Hube-Magg Martina Kluth Katharina Möller Anne Menz Andreas H Marx Till Krech Patrick Lebok Christoph Fraune Guido Sauter Ronald Simon Eike Burandt Sarah Minner Stefan Steurer Maximilian Lennartz Morton Freytag |
| author_facet | Seyma Büyücek Florian Viehweger Viktor Reiswich Natalia Gorbokon Viktoria Chirico Christian Bernreuther Florian Lutz Simon Kind Ria Schlichter Sören Weidemann Till S Clauditz Andrea Hinsch Ahmed Abdulwahab Bawahab Frank Jacobsen Andreas M Luebke David Dum Claudia Hube-Magg Martina Kluth Katharina Möller Anne Menz Andreas H Marx Till Krech Patrick Lebok Christoph Fraune Guido Sauter Ronald Simon Eike Burandt Sarah Minner Stefan Steurer Maximilian Lennartz Morton Freytag |
| author_sort | Seyma Büyücek |
| collection | DOAJ |
| description | Occludin is a key component of tight junctions. Reduced occludin expression has been linked to cancer progression in individual tumor types, but a comprehensive and standardized analysis across human tumor types is lacking. To study the prevalence and clinical relevance of occludin expression in cancer, a tissue microarray containing 16,870 samples from 148 different tumor types and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Occludin immunostaining was observed in 10,746 (76.6%) of 14,017 analyzable tumors, including 18.9% with weak, 16.2% with moderate, and 41.6% with strong staining intensity. Occludin positivity was found in 134 of 148 tumor categories and was most frequent in adenocarcinomas (37.5-100%) and neuroendocrine neoplasms (67.9-100%), less common in squamous cell carcinomas (23.8-93%) and in malignant mesotheliomas (up to 48.1%), and rare in Non-Hodgkin's lymphomas (1-2%) and most mesenchymal tumors. Reduced occludin staining was linked to adverse tumor features in several tumor types, including colorectal adenocarcinoma (advanced pT stage, p < 0.0001; L1 status, p = 0.0384; absence of microsatellite instability, p < 0.0001), pancreatic adenocarcinoma (advanced pT stage, p = 0.005), clear cell renal cell carcinoma (high ISUP grade, p < 0.0001; advanced pT stage, p < 0.0001; high UICC stage, p < 0.0001; distant metastasis, p = 0.0422; shortened overall or recurrence-free survival, p ≤ 0.0116), papillary renal cell carcinoma (high pT stage, p < 0.0001; high UICC stage, p = 0.0228; distant metastasis, p = 0.0338; shortened recurrence-free survival, p = 0.006), and serous high-grade ovarian cancer (advanced pT stage, p = 0.0133). Occludin staining was unrelated to parameters of tumor aggressiveness in breast, gastric, endometrial, and thyroidal cancer. Our data demonstrate significant levels of occludin expression in many different tumor entities and identify reduced occludin expression as a potentially useful prognostic feature in several tumor entities. |
| format | Article |
| id | doaj-art-ee75bd2b29fd4103b20445ddb5dd8142 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-ee75bd2b29fd4103b20445ddb5dd81422025-08-20T02:08:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01204e032110510.1371/journal.pone.0321105Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumors.Seyma BüyücekFlorian ViehwegerViktor ReiswichNatalia GorbokonViktoria ChiricoChristian BernreutherFlorian LutzSimon KindRia SchlichterSören WeidemannTill S ClauditzAndrea HinschAhmed Abdulwahab BawahabFrank JacobsenAndreas M LuebkeDavid DumClaudia Hube-MaggMartina KluthKatharina MöllerAnne MenzAndreas H MarxTill KrechPatrick LebokChristoph FrauneGuido SauterRonald SimonEike BurandtSarah MinnerStefan SteurerMaximilian LennartzMorton FreytagOccludin is a key component of tight junctions. Reduced occludin expression has been linked to cancer progression in individual tumor types, but a comprehensive and standardized analysis across human tumor types is lacking. To study the prevalence and clinical relevance of occludin expression in cancer, a tissue microarray containing 16,870 samples from 148 different tumor types and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Occludin immunostaining was observed in 10,746 (76.6%) of 14,017 analyzable tumors, including 18.9% with weak, 16.2% with moderate, and 41.6% with strong staining intensity. Occludin positivity was found in 134 of 148 tumor categories and was most frequent in adenocarcinomas (37.5-100%) and neuroendocrine neoplasms (67.9-100%), less common in squamous cell carcinomas (23.8-93%) and in malignant mesotheliomas (up to 48.1%), and rare in Non-Hodgkin's lymphomas (1-2%) and most mesenchymal tumors. Reduced occludin staining was linked to adverse tumor features in several tumor types, including colorectal adenocarcinoma (advanced pT stage, p < 0.0001; L1 status, p = 0.0384; absence of microsatellite instability, p < 0.0001), pancreatic adenocarcinoma (advanced pT stage, p = 0.005), clear cell renal cell carcinoma (high ISUP grade, p < 0.0001; advanced pT stage, p < 0.0001; high UICC stage, p < 0.0001; distant metastasis, p = 0.0422; shortened overall or recurrence-free survival, p ≤ 0.0116), papillary renal cell carcinoma (high pT stage, p < 0.0001; high UICC stage, p = 0.0228; distant metastasis, p = 0.0338; shortened recurrence-free survival, p = 0.006), and serous high-grade ovarian cancer (advanced pT stage, p = 0.0133). Occludin staining was unrelated to parameters of tumor aggressiveness in breast, gastric, endometrial, and thyroidal cancer. Our data demonstrate significant levels of occludin expression in many different tumor entities and identify reduced occludin expression as a potentially useful prognostic feature in several tumor entities.https://doi.org/10.1371/journal.pone.0321105 |
| spellingShingle | Seyma Büyücek Florian Viehweger Viktor Reiswich Natalia Gorbokon Viktoria Chirico Christian Bernreuther Florian Lutz Simon Kind Ria Schlichter Sören Weidemann Till S Clauditz Andrea Hinsch Ahmed Abdulwahab Bawahab Frank Jacobsen Andreas M Luebke David Dum Claudia Hube-Magg Martina Kluth Katharina Möller Anne Menz Andreas H Marx Till Krech Patrick Lebok Christoph Fraune Guido Sauter Ronald Simon Eike Burandt Sarah Minner Stefan Steurer Maximilian Lennartz Morton Freytag Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumors. PLoS ONE |
| title | Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumors. |
| title_full | Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumors. |
| title_fullStr | Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumors. |
| title_full_unstemmed | Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumors. |
| title_short | Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumors. |
| title_sort | reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types a tissue microarray study on 16 870 tumors |
| url | https://doi.org/10.1371/journal.pone.0321105 |
| work_keys_str_mv | AT seymabuyucek reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT florianviehweger reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT viktorreiswich reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT nataliagorbokon reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT viktoriachirico reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT christianbernreuther reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT florianlutz reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT simonkind reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT riaschlichter reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT sorenweidemann reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT tillsclauditz reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT andreahinsch reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT ahmedabdulwahabbawahab reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT frankjacobsen reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT andreasmluebke reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT daviddum reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT claudiahubemagg reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT martinakluth reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT katharinamoller reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT annemenz reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT andreashmarx reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT tillkrech reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT patricklebok reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT christophfraune reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT guidosauter reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT ronaldsimon reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT eikeburandt reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT sarahminner reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT stefansteurer reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT maximilianlennartz reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors AT mortonfreytag reducedoccludinexpressionisrelatedtounfavorabletumorphenotypeandpoorprognosisinmanydifferenttumortypesatissuemicroarraystudyon16870tumors |